MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $126.54M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.93M
Average 0.98M
Returns on capital
MacroGenics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-134.2%
avg -52.9%
ROIC
-33.0%
avg -43.6%
ROA
-29.1%
avg -29.4%
Analysis
ROA is currently the strongest return metric at -29.1% versus its period average of -29.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Eric Blasius Risser | Chief Executive Officer, President & Director | USD 977.47K | 53 | 0 | <0.01% |
Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer | USD 881.4K | 72 | 80.00K | 0.13% |
James Karrels | Senior VP & CFO | USD 845.55K | 59 | 0 | <0.01% |
Araba Lamouse-Smith | Vice President of Technical Operations | — | — | — | — |
Frank George Perabo FEBU | Vice President & Interim Head of Clinical Development | — | 62 | — | — |
Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning | — | — | — | — |
Jeffrey Stuart Peters | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | — | 55 | 0 | <0.01% |
Beth Smith | Vice President, Controller & Treasurer | — | 58 | — | — |
Steve Harig | Senior Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$129,085.75
Net Transaction Value
−$129,085.75
Net selling
Most Active
Peters Jeffrey Stuart
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 19, 26Aug 19, 2026 | Peters Jeffrey Stuart Direct | Sell | $129.1K$129,085.75 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $129,085.75 over the last 12 months. That adds up to net selling of $129,085.75. Peters Jeffrey Stuart was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -0.1% | -4.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.1% over three years. Forward estimates point to Revenue at -4.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does MacroGenics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MGNX's management, answered from reported figures.
Who manages MGNX?
MacroGenics, Inc. (MGNX) lists 9 active executives. The top listed executive is Araba Lamouse-Smith, Vice President of Technical Operations.
Are MGNX insiders buying or selling?
Recent insider activity shows net buying of $4.68M.
Continue the stock analysis
Jump to another research area for this company.